230 related articles for article (PubMed ID: 24504686)
1. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus.
Sinha VP; Howey DC; Choi SL; Mace KF; Heise T
Diabetes Obes Metab; 2014 Apr; 16(4):344-50. PubMed ID: 24118909
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
Linnebjerg H; Choi SL; Lam EC; Mace KF; Hodgson TS; Sinha VP
Clin Pharmacol Drug Dev; 2016 May; 5(3):216-24. PubMed ID: 27163501
[TBL] [Abstract][Full Text] [Related]
4. Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial.
Morrow LA; Hompesch M; Jacober SJ; Leng Choi S; Qu Y; Sinha VP
Diabetes Obes Metab; 2016 Nov; 18(11):1065-1071. PubMed ID: 27169522
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
de la Peña A; Yeo KP; Linnebjerg H; Catton E; Reddy S; Brown-Augsburger P; Morrow L; Ignaut DA
J Diabetes Sci Technol; 2015 Jul; 9(4):824-30. PubMed ID: 25697717
[TBL] [Abstract][Full Text] [Related]
6. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR; Mudaliar S; Ciaraldi TP; Armstrong DA; Burke P; Pettus J; Garhyan P; Choi SL; Jacober SJ; Knadler MP; Lam EC; Prince MJ; Bose N; Porksen N; Sinha VP; Linnebjerg H
Diabetes Care; 2014 Sep; 37(9):2609-15. PubMed ID: 24947791
[TBL] [Abstract][Full Text] [Related]
7. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine.
Bergenstal RM; Rosenstock J; Bastyr EJ; Prince MJ; Qu Y; Jacober SJ
Diabetes Care; 2014; 37(3):659-65. PubMed ID: 24198302
[TBL] [Abstract][Full Text] [Related]
8. A clinical utility index for selecting an optimal insulin dosing algorithm for LY2605541 in patients with type 2 diabetes pretreated with basal insulin.
Manner DH; Luo J; Qu Y; Berry S; Gaydos BL; Jacober SJ
Diabetes Technol Ther; 2014 Aug; 16(8):499-505. PubMed ID: 24825416
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
10. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
13. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM; Rosenstock J; Arakaki RF; Prince MJ; Qu Y; Sinha VP; Howey DC; Jacober SJ
Diabetes Care; 2012 Nov; 35(11):2140-7. PubMed ID: 22787177
[TBL] [Abstract][Full Text] [Related]
15. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
Caparrotta TM; Evans M
Diabetes Obes Metab; 2014 May; 16(5):388-95. PubMed ID: 23941279
[TBL] [Abstract][Full Text] [Related]
16. Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects.
Becker RH; Frick AD; Teichert L; Nosek L; Heinemann L; Heise T; Rave K
Diabetes Obes Metab; 2008 Nov; 10(11):1105-13. PubMed ID: 18355326
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
[TBL] [Abstract][Full Text] [Related]
18. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
[TBL] [Abstract][Full Text] [Related]
19. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]